Skip to main content
SpringerLink
Log in

SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case–control study

  • Pharmacogenetics
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

This nested case–control study aimed to evaluate the association of candidate genetic variants with statin-induced myotoxicity in Chinese patients with coronary artery disease (CAD).

Methods

One hundred forty-eight Chinese patients experiencing statin-induced myotoxicity were included in our study, and 255 patients without muscular side effects served as controls. Five SNPs in CYP3A5, SLCO1B1, and APOE were genotyped. The effect of genetic variants on statin-induced myotoxicity was assessed.

Results

Patients who carried at least one SLCO1B1 521C allele had a higher risk for myotoxicity (OR = 1.69, 95%CI = 1.07–2.67, P = 0.024). Significant association was found between SLCO1B1 521C mutant allele mutation and risk of myotoxicity in individuals that received rosuvastatin (OR = 3.67, 95%CI = 1.42–9.47, P = 0.007). However, non-significant association was observed between 521C mutant allele and risk of myotoxicity (P > 0.5) in patients that received atorvastatin and simvastatin. The other four single nucleotide polymorphisms (SNPs), namely rs776746, rs2306283, rs7412, and rs429358, showed no significant association with any statin induced myotoxicity (P > 0.5).

Conclusions

SLCO1B1 (rs4149056, 521T > C) is associated with statin-induced myotoxicity in Chinese patients with coronary artery disease. In addition, SLCO1B1 521C mutant allele increased the risk of rosuvastatin-associated myotoxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Joy TR, Hegele RA (2009) Narrative review: statin-related myopathy. Ann Intern Med 150(12):858–868

    Article  PubMed  Google Scholar 

  2. Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, Gurwitz JH, Chan KA, Goodman MJ, Platt R (2004) Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 292(21):2585–2590. doi:10.1001/jama.292.21.2585

    Article  CAS  PubMed  Google Scholar 

  3. Taha DA, De Moor CH, Barrett DA, Gershkovich P (2014) Translational insight into statin-induced muscle toxicity: from cell culture to clinical studies. Transl Res: J LabClin Med 164(2):85–109. doi:10.1016/j.trsl.2014.01.013

    Article  CAS  Google Scholar 

  4. El-Salem K, Ababneh B, Rudnicki S, Malkawi A, Alrefai A, Khader Y, Saadeh R, Saydam M (2011) Prevalence and risk factors of muscle complications secondary to statins. Muscle Nerve 44(6):877–881. doi:10.1002/mus.22205

    Article  PubMed  Google Scholar 

  5. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R (2008) SLCO1B1 variants and statin-induced myopathy—a genomewide study. N Engl J Med 359(8):789–799. doi:10.1056/NEJMoa0801936

    Article  CAS  PubMed  Google Scholar 

  6. Hermann M, Bogsrud MP, Molden E, Asberg A, Mohebi BU, Ose L, Retterstol K (2006) Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy. Clin Pharmacol Ther 79(6):532–539. doi:10.1016/j.clpt.2006.02.014

    Article  CAS  PubMed  Google Scholar 

  7. Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M (2007) Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 82(6):726–733. doi:10.1038/sj.clpt.6100220

    Article  CAS  PubMed  Google Scholar 

  8. Niemi M, Pasanen MK, Neuvonen PJ (2006) SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther 80(4):356–366. doi:10.1016/j.clpt.2006.06.010

    Article  CAS  PubMed  Google Scholar 

  9. Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M (2006) SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 16(12):873–879. doi:10.1097/01.fpc.0000230416.82349.90

    Article  CAS  PubMed  Google Scholar 

  10. de Keyser CE, Peters BJ, Becker ML, Visser LE, Uitterlinden AG, Klungel OH, Verstuyft C, Hofman A, Maitland-van der Zee AH, Stricker BH (2014) The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study. Pharmacogenet Genomics 24(1):43–51. doi:10.1097/fpc.0000000000000018

    Article  PubMed  Google Scholar 

  11. Carr DF, O'Meara H, Jorgensen AL, Campbell J, Hobbs M, McCann G, van Staa T, Pirmohamed M (2013) SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink. Clin Pharmacol Ther 94(6):695–701. doi:10.1038/clpt.2013.161

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Voora D, Shah SH, Spasojevic I, Ali S, Reed CR, Salisbury BA, Ginsburg GS (2009) The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 54(17):1609–1616. doi:10.1016/j.jacc.2009.04.053

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Ferrari M, Guasti L, Maresca A, Mirabile M, Contini S, Grandi AM, Marino F, Cosentino M (2014) Association between statin-induced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2. Eur J Clin Pharmacol 70(5):539–547. doi:10.1007/s00228-014-1661-6

    Article  CAS  PubMed  Google Scholar 

  14. Linde R, Peng L, Desai M, Feldman D (2010) The role of vitamin D and SLCO1B1*5 gene polymorphism in statin-associated myalgias. Dermato-endocrinology 2(2):77–84. doi:10.4161/derm.2.2.13509

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Danik JS, Chasman DI, MacFadyen JG, Nyberg F, Barratt BJ, Ridker PM (2013) Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy. Am Heart J 165(6):1008–1014. doi:10.1016/j.ahj.2013.01.025

    Article  CAS  PubMed  Google Scholar 

  16. Puccetti L, Ciani F, Auteri A (2010) Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study. Atherosclerosis 211(1):28–29

    Article  CAS  PubMed  Google Scholar 

  17. Khine H, Yuet WC, Adams-Huet B, Ahmad Z (2016) Statin-associated muscle symptoms and SLCO1B1 rs4149056 genotype in patients with familial hypercholesterolemia. Am Heart J 179:1–9. doi:10.1016/j.ahj.2016.05.015

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Kim KA, Park PW, Lee OJ, Kang DK, Park JY (2007) Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. J Clin Pharmacol 47(1):87–93. doi:10.1177/0091270006295063

    Article  CAS  PubMed  Google Scholar 

  19. Birmingham BK, Bujac SR, Elsby R, Azumaya CT, Wei C, Chen Y, Mosqueda-Garcia R, Ambrose HJ (2015) Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect? Eur J Clin Pharmacol 71(3):341–355. doi:10.1007/s00228-014-1801-z

    Article  CAS  PubMed  Google Scholar 

  20. Lee HK, Hu M, Lui S, Ho CS, Wong CK, Tomlinson B (2013) Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients. Pharmacogenomics 14(11):1283–1294. doi:10.2217/pgs.13.115

    Article  CAS  PubMed  Google Scholar 

  21. Kitzmiller JP, Luzum JA, Baldassarre D, Krauss RM, Medina MW (2014) CYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort. Pharmacogenet Genomics 24(10):486–491. doi:10.1097/FPC.0000000000000079

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Hou Q, Li S, Li L, Li Y, Sun X, Tian H (2015) Association between SLCO1B1 gene T521C polymorphism and statin-related myopathy risk: a meta-analysis of case-control studies. Medicine 94(37):e1268. doi:10.1097/md.0000000000001268

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H, Moore R, Lee C, Chen Y, Schneck D (2005) Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 78(4):330–341. doi:10.1016/j.clpt.2005.06.013

    Article  CAS  PubMed  Google Scholar 

  24. Birmingham BK, Bujac SR, Elsby R, Azumaya CT, Zalikowski J, Chen Y, Kim K, Ambrose HJ (2015) Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States. Eur J Clin Pharmacol 71(3):329–340. doi:10.1007/s00228-014-1800-0

    Article  CAS  PubMed  Google Scholar 

  25. DeGorter MK, Tirona RG, Schwarz UI, Choi YH, Dresser GK, Suskin N, Myers K, Zou G, Iwuchukwu O, Wei WQ, Wilke RA, Hegele RA, Kim RB (2013) Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. Circ Cardiovasc Genet 6(4):400–408. doi:10.1161/circgenetics.113.000099

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Donnelly LA, Doney AS, Tavendale R, Lang CC, Pearson ER, Colhoun HM, McCarthy MI, Hattersley AT, Morris AD, Palmer CN (2011) Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study. Clin Pharmacol Ther 89(2):210–216. doi:10.1038/clpt.2010.255

    Article  CAS  PubMed  Google Scholar 

  27. Nies AT, Niemi M, Burk O, Winter S, Zanger UM, Stieger B, Schwab M, Schaeffeler E (2013) Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1. Genome Med 5(1):1. doi:10.1186/gm405

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Jiang J, Tang Q, Feng J, Dai R, Wang Y, Yang Y, Tang X, Deng C, Zeng H, Zhao Y, Zhang F (2016) Association between SLCO1B1 -521T>C and -388A>G polymorphisms and risk of statin-induced adverse drug reactions: a meta-analysis. SpringerPlus 5(1):1368. doi:10.1186/s40064-016-2912-z

    Article  PubMed  PubMed Central  Google Scholar 

  29. Gupta A, Thompson D, Whitehouse A, Collier T, Dahlof B, Poulter N, Collins R, Sever P (2017) Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian cardiac outcomes trial-lipid-lowering arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet (London, England) 389(10088):2473–2481. doi:10.1016/s0140-6736(17)31075-9

    Article  CAS  Google Scholar 

  30. Thompson PD, Clarkson P, Karas RH (2003) Statin-associated myopathy. JAMA 289(13):1681–1690. doi:10.1001/jama.289.13.1681

    Article  CAS  PubMed  Google Scholar 

  31. Elhayany A, Mishaal RA, Vinker S (2012) Is there clinical benefit to routine enzyme testing of patients on statins? Expert Opin Drug Saf 11(2):185–190. doi:10.1517/14740338.2012.630659

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by the National Nature Science Foundation of China (81373486, 81673514), National key R&D program (no. 2017YFC0909301, 2016YFC0905000), Science and Technology Development Projects of Guangdong Province, China (2016B090918114, 2013B021800157), and Science and Technology Development Projects of Guangzhou, Guangdong, China (201510010236, 201604020096).

Author information

Author notes

  1. Ju-E Liu, Xiao-Ying Liu, and Sheng Chen contributed equally to this work.

Authors and Affiliations

  1. Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention, Guangdong Cardiovascular Institute, Guangzhou, 510080, China

    Ju-E Liu, Xiao-Ying Liu, Li-Yun Cai & Shi-Long Zhong

  2. Medical Research Center of Guangdong General Hospital, Guangdong Cardiovascular Institute, Guangdong Academy of Medical Sciences, 106 Zhongshan Road, Weilun Bldg.1112, Guangzhou, 510080, People’s Republic of China

    Ju-E Liu, Xiao-Ying Liu, Li-Yun Cai & Shi-Long Zhong

  3. Department of Pharmacy of Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, China

    Ju-E Liu, Min Yang & Wei-Hua Lai

  4. Department of General Surgery of Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, China

    Sheng Chen

  5. Guangzhou Higher Education Mega Center Health Industrial Science and Technology Park Investment Management Co. Ltd. Guangzhou Gene Denovo Biotechnology Co. Ltd, Guangzhou, China

    Yan Zhang

  6. Department of Pharmacy, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, 510080, China

    Bin Ren

Authors
  1. Ju-E Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiao-Ying Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sheng Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yan Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Li-Yun Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Min Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Wei-Hua Lai
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Bin Ren
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Shi-Long Zhong
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

In this project, SLZ and WHL contributed for the design and management; JEL, XYL, SC, BR, and SLZ contributed to performing experiment and data analysis; JEL, LYC, and SC contributed to the patient recruitment; JEL and YZ contributed to writing of the manuscript; MY and BR contributed to revised the manuscript. All authors approved the final version of the manuscript.

Corresponding author

Correspondence to Shi-Long Zhong.

Ethics declarations

Conflict of interest

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liu, JE., Liu, XY., Chen, S. et al. SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case–control study. Eur J Clin Pharmacol 73, 1409–1416 (2017). https://doi.org/10.1007/s00228-017-2318-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-017-2318-z

Keywords

Search

Navigation